|
Gene: TNFRSF10B |
Gene summary for TNFRSF10B |
Gene summary. |
Gene information | Species | Human | Gene symbol | TNFRSF10B | Gene ID | 8795 |
Gene name | TNF receptor superfamily member 10b | |
Gene Alias | CD262 | |
Cytomap | 8p21.3 | |
Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | O14763 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8795 | TNFRSF10B | CCI_1 | Human | Cervix | CC | 2.91e-02 | 5.41e-01 | 0.528 |
8795 | TNFRSF10B | CCI_3 | Human | Cervix | CC | 5.63e-08 | 5.28e-01 | 0.516 |
8795 | TNFRSF10B | sample3 | Human | Cervix | CC | 7.34e-03 | 1.14e-01 | 0.1387 |
8795 | TNFRSF10B | AEH-subject1 | Human | Endometrium | AEH | 5.35e-23 | 6.15e-01 | -0.3059 |
8795 | TNFRSF10B | AEH-subject2 | Human | Endometrium | AEH | 8.58e-07 | 3.82e-01 | -0.2525 |
8795 | TNFRSF10B | AEH-subject3 | Human | Endometrium | AEH | 5.23e-07 | 3.93e-01 | -0.2576 |
8795 | TNFRSF10B | AEH-subject4 | Human | Endometrium | AEH | 7.29e-08 | 4.71e-01 | -0.2657 |
8795 | TNFRSF10B | AEH-subject5 | Human | Endometrium | AEH | 3.66e-14 | 5.29e-01 | -0.2953 |
8795 | TNFRSF10B | EEC-subject1 | Human | Endometrium | EEC | 4.63e-23 | 7.13e-01 | -0.2682 |
8795 | TNFRSF10B | EEC-subject2 | Human | Endometrium | EEC | 8.83e-07 | 4.14e-01 | -0.2607 |
8795 | TNFRSF10B | EEC-subject3 | Human | Endometrium | EEC | 5.57e-04 | 3.70e-01 | -0.2525 |
8795 | TNFRSF10B | EEC-subject4 | Human | Endometrium | EEC | 5.84e-15 | 5.59e-01 | -0.2571 |
8795 | TNFRSF10B | EEC-subject5 | Human | Endometrium | EEC | 6.56e-07 | 3.87e-01 | -0.249 |
8795 | TNFRSF10B | GSM5276934 | Human | Endometrium | EEC | 2.46e-04 | 3.14e-01 | -0.0913 |
8795 | TNFRSF10B | GSM5276937 | Human | Endometrium | EEC | 2.58e-09 | 4.12e-01 | -0.0897 |
8795 | TNFRSF10B | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.64e-04 | 1.45e-01 | -0.1869 |
8795 | TNFRSF10B | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 4.75e-04 | 1.05e-01 | -0.1883 |
8795 | TNFRSF10B | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.93e-05 | 2.46e-01 | -0.1934 |
8795 | TNFRSF10B | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 8.94e-03 | -2.65e-02 | -0.1917 |
8795 | TNFRSF10B | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.39e-03 | 4.07e-02 | -0.1916 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:009719110 | Cervix | CC | extrinsic apoptotic signaling pathway | 52/2311 | 219/18723 | 2.06e-06 | 6.34e-05 | 52 |
GO:003497610 | Cervix | CC | response to endoplasmic reticulum stress | 57/2311 | 256/18723 | 5.81e-06 | 1.42e-04 | 57 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00700599 | Cervix | CC | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 21/2311 | 63/18723 | 1.18e-05 | 2.51e-04 | 21 |
GO:00096127 | Cervix | CC | response to mechanical stimulus | 48/2311 | 216/18723 | 3.23e-05 | 5.29e-04 | 48 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00712602 | Cervix | CC | cellular response to mechanical stimulus | 23/2311 | 81/18723 | 8.34e-05 | 1.12e-03 | 23 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:00431237 | Cervix | CC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 37/2311 | 186/18723 | 2.15e-03 | 1.55e-02 | 37 |
GO:00086259 | Cervix | CC | extrinsic apoptotic signaling pathway via death domain receptors | 19/2311 | 82/18723 | 4.57e-03 | 2.77e-02 | 19 |
GO:009719316 | Endometrium | AEH | intrinsic apoptotic signaling pathway | 75/2100 | 288/18723 | 1.46e-12 | 2.83e-10 | 75 |
GO:003497616 | Endometrium | AEH | response to endoplasmic reticulum stress | 62/2100 | 256/18723 | 2.88e-09 | 2.13e-07 | 62 |
GO:009719116 | Endometrium | AEH | extrinsic apoptotic signaling pathway | 49/2100 | 219/18723 | 1.58e-06 | 4.94e-05 | 49 |
GO:00431229 | Endometrium | AEH | regulation of I-kappaB kinase/NF-kappaB signaling | 52/2100 | 249/18723 | 6.58e-06 | 1.59e-04 | 52 |
GO:00431238 | Endometrium | AEH | positive regulation of I-kappaB kinase/NF-kappaB signaling | 41/2100 | 186/18723 | 1.59e-05 | 3.32e-04 | 41 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541727 | Endometrium | EEC | Lipid and atherosclerosis | 48/1237 | 215/8465 | 1.41e-03 | 9.07e-03 | 6.77e-03 | 48 |
hsa0421024 | Endometrium | EEC | Apoptosis | 31/1237 | 136/8465 | 6.72e-03 | 3.25e-02 | 2.42e-02 | 31 |
hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513036 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa0541736 | Endometrium | EEC | Lipid and atherosclerosis | 48/1237 | 215/8465 | 1.41e-03 | 9.07e-03 | 6.77e-03 | 48 |
hsa0421034 | Endometrium | EEC | Apoptosis | 31/1237 | 136/8465 | 6.72e-03 | 3.25e-02 | 2.42e-02 | 31 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0411524 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa0411534 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0513214 | Liver | NAFLD | Salmonella infection | 55/1043 | 249/8465 | 8.48e-06 | 3.09e-04 | 2.49e-04 | 55 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNFRSF10B | SNV | Missense_Mutation | novel | c.1284N>A | p.Phe428Leu | p.F428L | O14763 | protein_coding | deleterious(0.01) | benign(0.125) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNFRSF10B | SNV | Missense_Mutation | novel | c.1030G>T | p.Asp344Tyr | p.D344Y | O14763 | protein_coding | tolerated(0.12) | benign(0.001) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNFRSF10B | insertion | Frame_Shift_Ins | novel | c.858_859insACTAGCCTGGCCAACATGGTGAAACCCTGTCT | p.Gln287ThrfsTer63 | p.Q287Tfs*63 | O14763 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TNFRSF10B | insertion | In_Frame_Ins | novel | c.955_956insTCGTCCCGAGATCTGGGCAGCATTGCTCGGTCTTTG | p.Arg319delinsIleValProArgSerGlyGlnHisCysSerValPheGly | p.R319delinsIVPRSGQHCSVFG | O14763 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TNFRSF10B | SNV | Missense_Mutation | rs748928192 | c.826N>A | p.Val276Met | p.V276M | O14763 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TNFRSF10B | SNV | Missense_Mutation | novel | c.187N>T | p.Pro63Ser | p.P63S | O14763 | protein_coding | tolerated(0.29) | benign(0.264) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TNFRSF10B | SNV | Missense_Mutation | c.864N>C | p.Glu288Asp | p.E288D | O14763 | protein_coding | tolerated(0.22) | possibly_damaging(0.76) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TNFRSF10B | SNV | Missense_Mutation | rs529765232 | c.344N>A | p.Arg115His | p.R115H | O14763 | protein_coding | tolerated(0.16) | possibly_damaging(0.87) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TNFRSF10B | SNV | Missense_Mutation | c.791G>A | p.Arg264Gln | p.R264Q | O14763 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
TNFRSF10B | SNV | Missense_Mutation | c.1189N>A | p.Ala397Thr | p.A397T | O14763 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | agonist | CHEMBL2107846 | DULANERMIN | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | antibody | APOMAB | APOMAB | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | LUTEOLIN | LUTEOLIN | 21265555 | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | HGS-TR2J | |||
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | Conatumumab | CONATUMUMAB | ||
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | antibody | 318164853 | TIGATUZUMAB | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | antibody | DULANERMIN | DULANERMIN | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | Anti-DR5 cells | |||
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | antibody | DULANERMIN | DULANERMIN | |
8795 | TNFRSF10B | DRUGGABLE GENOME, CELL SURFACE | LEXATUMUMAB | LEXATUMUMAB |
Page: 1 2 3 |